Clostridium difficile is the most common healthcare-associated infection in the United States. In the United States alone, C difficile infection (CDI) causes approximately 500,000 infections and 30,000 deaths annually.1 In the early 2000s, a substantial increase in CDI incidence and severity were noted in both the United States and Canada.2 Further investigation indicated that a particular C difficile strain, known as ribotype (RT) 027, was causing the majority of CDIs in both countries. Compared with previous endemic strains, this strain was found to be resistant to fluoroquinolones and to produce a novel binary toxin. In addition, RT027 also had acquired a loss-of-function mutation in tcdC, a negative regulator of the production of toxins A and B. Several microbiologic characteristics were posited to lead to the emergence and global dissemination of RT027, including fluoroquinolone resistance, particularly in the setting of widely increasing fluoroquinolone use in adults, and potentially increased sporulation efficiency. In subsequent years, the emergence of RT078 was noted. Despite their phylogenetic distance, like RT027, RT078 produces binary toxin and has the same tcdC mutation, although fluoroquinolone resistance is less common. Because of the identification of genetically similar strains of RT078 in livestock and humans, the role of animals and foods as potential reservoirs of RT078 has been proposed.
Of note, the timeline of expanded dietary trehalose coincides with the rise of CDI, particularly the rise of infections caused by RT027 and RT078. Britton and colleagues have investigated this interesting ecological observation through their identification of a mechanism of C difficile trehalose metabolism. All C difficile strains can utilize trehalose as a carbon source through the activity of a phosphotrehalase enzyme encoded by the treA gene. However, compared with other C difficile strains, RT027 and RT078 are able to grow robustly at low concentrations of trehalose. This enhanced growth seems to be related to genetic modifications in genes that contribute to trehalose metabolism, although the specific genetic modifications in RT027 and RT078 are quite different. RT027 has acquired a mutation in the gene that represses treA, leading to excess production of treA in the presence of trehalose, resulting in more efficient trehalose utilization by RT027 strains.
The importance of treA in C difficile pathogenesis was confirmed in an animal model of infection in which animals infected with a genetically modified RT027 strain that was missing the treA gene had improved outcomes compared with animals infected with the wild type RT027 strain. RT078, on the other hand, does not have a mutated treA repressor gene. Instead, RT078 has uniquely acquired 4 additional genes that allow it to metabolize trehalose more efficiently. Thus, the identification of 2 distinct genetic modifications that augment the same biochemical pathway strongly supports the role of dietary trehalose in the increased incidence of CDI caused by RT027 and RT078.
While these epidemiologic, microbiologic, and genomic data are compelling, several other epidemiologic observations suggest that other factors in addition to dietary trehalose likely contributed to the observed shifts in CDI clinical and molecular epidemiology. For example, in Canada, the outbreak of RT027 in 2002 predated expanded use of trehalose in 2005. Furthermore, recent data from the US Centers for Disease Control and Prevention (CDC) suggest that RT027 is declining, and RT078 is relatively uncommon, despite no active measures being taken to reduce dietary trehalose.4 Furthermore, compared with adults, RT027 and RT078 have not predominated in pediatric populations, although pediatric molecular epidemiologic investigation is quite limited. Thus, while dietary trehalose may provide a selective advantage to these epidemic strains, there also appear to be other factors that have contributed to the observed shifts in CDI clinical and molecular epidemiology.
The clinical implications of this finding are currently unknown. While therapeutic options for CDI have expanded in recent years with the development of narrow-spectrum antibiotics (eg, fidaxomicin), immunologics (eg, monoclonal antibody against toxin B), and biotherapeutics (eg, fecal microbiota transplantation), the frequency of severe and/or recurrent CDI remains unacceptably high.5 Thus, there remains a need for novel therapeutic strategies, such as a low-trehalose diet, for CDI treatment and prevention, and this is a potential area of future clinical investigation. The clinical benefit of such strategies should be proven before wide-scale changes to trehalose use in food manufacturing are undertaken.
Larry K. Kociolek, MD, MSCI, is the associate medical director of Infection Prevention and Control at The Ann & Robert H. Lurie Children’s Hospital of Chicago and assistant professor of Pediatrics at the Northwestern University Feinberg School of Medicine in Illinois.
- Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. New Engl J Med. 2015;372(9):825-834.
- Freeman J, Bauer MP, Baines D, et al. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev. 2010;23(3):529-549.
- Collins J, Robinson C, Danhof H, et al. Dietary trehalose enhances virulence of epidemic Clostridium difficile. Nature. 2018;553(7688):291-294.
- Karlsson M, Paulick A, Albreght V, et al, EIP CDI Pathogen Group. 2016. Molecular epidemiology of Clostridium difficile isolated in the United States, 2014. Presented at: 13th Biennial Congress of the Anaerobe Society of the Americas; Nashville, Tennessee; July 11-14, 2016. Abstract PIII-4.
- Kociolek LK, Gerding DN. Breakthroughs in the treatment and prevention of Clostridium difficile infection. Nat Rev Gastroenterol Hepatol. 2016;13(3):150-160.